A new personalized cancer vaccine developed by Moderna and Merck has demonstrated strong results in a clinical trial involving melanoma patients. When paired with an immunotherapy drug, the vaccine significantly reduced the risk of cancer returning after initial treatment. The approach uses each patient’s unique tumor mutations to create a custom vaccine designed to train the immune system to recognize and attack remaining cancer cells. This targeted strategy marks a major advancement in precision medicine, offering a tailored solution that goes beyond one-size-fits-all treatments.
The BBC News video explains the science behind the vaccine, detailing how it is produced using mRNA technology and how it activates the body's natural defenses. While the trial results are promising, challenges remain in scaling up production to make the treatment widely available. Researchers are exploring whether this method can be applied to other types of cancer. If successful, this innovation could transform how cancers are treated, shifting toward more individualized and effective therapies based on a patient’s specific genetic profile.